# Atezolizumab Plus Bevacizumab With HCC and HBV Infection

> **NCT04180072** · NA · ACTIVE_NOT_RECRUITING · sponsor: **National Health Research Institutes, Taiwan** · enrollment: 51 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT04180072
- **Lead sponsor:** National Health Research Institutes, Taiwan
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-03-12
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2026-04-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04180072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04180072, "Atezolizumab Plus Bevacizumab With HCC and HBV Infection". Retrieved via AI Analytics 2026-07-29 from https://api.ai-analytics.org/clinical/NCT04180072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*